ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMAGet Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 7,990,000 shares, an increase of 18.9% from the February 29th total of 6,720,000 shares. Based on an average trading volume of 2,670,000 shares, the short-interest ratio is presently 3.0 days.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $6.60 on Monday. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -50.77 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $6.76. The firm has a 50-day moving average of $5.65 and a two-hundred day moving average of $4.50.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The business had revenue of $73.90 million during the quarter, compared to analyst estimates of $73.50 million. On average, research analysts forecast that ADMA Biologics will post 0.3 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the sale, the director now directly owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 639,895 shares of company stock worth $3,927,169. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently modified their holdings of ADMA. Virtu Financial LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $34,000. Envestnet Asset Management Inc. bought a new position in shares of ADMA Biologics during the 1st quarter worth approximately $35,000. Price T Rowe Associates Inc. MD bought a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $35,000. Stephens Consulting LLC bought a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $36,000. Finally, Cerity Partners LLC bought a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $37,000. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of recent analyst reports. Cantor Fitzgerald lifted their price target on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Finally, Mizuho boosted their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and an average price target of $7.88.

View Our Latest Analysis on ADMA Biologics

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.